Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the expertise of a company focused on systemic mastocytosis (SM) and other KIT-driven diseases.
In June 2025, Sanofi agreed to acquire Blueprint for an equity value of $9.1bn.
Go deeper with GlobalData
The acquisition of Blueprint provides Sanofi with a well-established foothold among dermatologists, allergists and immunologists, which strengthens Sanofi’s efforts in advancing its expanding immunology pipeline.
It also includes Ayvakit/Ayvakyt (avapritinib), a treatment for rare immunological diseases that has received approval in both the US and the European Union.
The acquisition also covers elenestinib, a treatment for SM. It is currently being evaluated in the HARBOR study, a Phase II/III clinical trial. This ongoing, randomised, double-blind, placebo-controlled study aims to assess the efficacy and safety of elenestinib in combination with symptom-directed therapy for patients with indolent ISM and SM.
Sanofi has acquired BLU-808, an investigational oral medication that serves as a highly potent and selective inhibitor of wild-type KIT.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe tender offer for all outstanding Blueprint common stock shares expired on 17 July 2025. All conditions were met, and Sanofi accepted and will pay for all valid tendered shares.
Sanofi completed its acquisition of Blueprint through a merger, with the latter becoming a wholly owned subsidiary.
The transaction is financed with cash and commercial paper proceeds and will not significantly impact Sanofi’s 2025 financial guidance. It is expected to enhance gross margin and contribute positively to operating income and earnings per share after 2026.
In mid-July 2025, Thermo Fisher announced the acquisition of Sanofi’s sterile manufacturing facility in the US. The transaction is expected to be finalised in the second quarter of 2025, pending the usual closing conditions.
